Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Current Deferred Revenue (2016)

Amphastar Pharmaceuticals (AMPH) has 4 years of Current Deferred Revenue data on record, last reported at $830000.0 in Q3 2016.

  • For Q3 2016, Current Deferred Revenue rose 29.08% year-over-year to $830000.0; the TTM value through Sep 2016 reached $830000.0, up 29.08%, while the annual FY2015 figure was $643000.0, 95.41% down from the prior year.
  • Current Deferred Revenue reached $830000.0 in Q3 2016 per AMPH's latest filing, down from $1.7 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $14.6 million in Q3 2014 and bottomed at $643000.0 in Q4 2013.
  • Average Current Deferred Revenue over 4 years is $4.1 million, with a median of $830000.0 recorded in 2016.
  • Peak YoY movement for Current Deferred Revenue: surged 2079.32% in 2014, then tumbled 95.59% in 2015.
  • A 4-year view of Current Deferred Revenue shows it stood at $643000.0 in 2013, then soared by 2079.32% to $14.0 million in 2014, then plummeted by 95.41% to $643000.0 in 2015, then increased by 29.08% to $830000.0 in 2016.
  • Per Business Quant database, its latest 3 readings for Current Deferred Revenue were $830000.0 in Q3 2016, $1.7 million in Q2 2016, and $643000.0 in Q1 2016.